SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents

Pharmacology Biochemistry and Behavior

Volumn 102, Issue 2, 2012, Pages 203-214

  Griebel, Guy ^a   Pichat, Philippe ^a   Pruniaux, Marie Pierre ^a   Beeské, Sandra ^a   Lopez Grancha, Mati ^a   Genet, Elisabeth ^a   Terranova, Jean Paul ^a   Castro, Antonio ^b   Sánchez, Juan Antonio ^c   Black, Mark ^a   Varty, Geoffrey B ^a   Weiner, Ina ^d   Arad, Michal ^d   Barak, Segev ^d   De Levie, Amaya ^d   Guillot, Etienne ^a  

^a SANOFI   (France)

^b Sanofi Synthelabo   (Spain)

^c Life Length   (Spain)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Attention deficit hyperactivity disorder; Cognitive impairment associated with schizophrenia; Histamine H3 receptor; Rodents

Indexed keywords

HISTAMINE H3 RECEPTOR ANTAGONIST; NITRIC OXIDE SYNTHASE; PHENCYCLIDINE; SAR 110894; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATION LEARNING; DRUG EFFICACY; EPISODIC MEMORY; FEMALE; LATENT INHIBITION; MALE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; SCHIZOPHRENIA; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; COGNITION; FEMALE; HISTAMINE H3 ANTAGONISTS; MAZE LEARNING; MICE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SCHIZOPHRENIA;

ANIMALIA; CAVIA; MUS; RATTUS; RODENTIA;

EID: 84861029254     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.04.004     Document Type: Article

References (49)

1. 3 receptor. Trends Pharmacol Sci 2007;28:350-7.
2. Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I. Pro-cognitive and antipsychotic efficacy of the α7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 2009;34:1753-63.
3. 3 antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats. Psychopharmacology (Berl) 2009;205:589-97.
4. 3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats. Neuropharmacology 2010;59:492-502.
5. 3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APPTg2576mousemodel of Alzheimer's disease. Neurobiol Learn Mem 2011;95:64-72.
6. 3 antagonist thioperamide dosedependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behav Brain Res 2004;154:211-9.
7. Blandina P, Passani MB. Central histaminergic system interactions and cognition. EXS 2006;98:149-63.
8. 3 receptor activation in rats. Br J Pharmacol 1996;119:1656-64.
9. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336:38-46.
10. 3 receptor antagonists in dementias. Drug News Perspect 2010;23:99-103.
11. Chen SY, Wright JW, Barnes CD. The neurochemical and behavioral effects of β-amyloid peptide(25-35). Brain Res 1996;720:54-60.
12. Dornan WA, Kang DE, McCampbell A, Kang EE. Bilateral injections of beta A(25-35) + IBO into the hippocampus disrupts acquisition of spatial learning in the rat. Neuroreport 1993;5:165-8.
13. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 1988;31:47-59.
14. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol 2004;68:933-45.
15. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. Trends Mol Med 2011;17:689-98.
16. 3 receptor antagonist clobenpropit protects against Aβ42-induced neurotoxicity in differentiated rat PC12 cells. Pharmazie 2010;65:257-60.
17. Furfine ES, Harmon MF, Paith JE, Garvey EP. Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry 1993;32:8512-7.
18. Gaisler-Salomon I, Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl) 2003;166:333-42.
19. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, et al. JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 2009;56:1131-7.
20. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.
21. 3-R) antagonist : I. binding and functional characterization. Program no. 160. 21. 2008 neuroscience meeting planner.Washington, DC: Society for Neuroscience; 2008. November 15-19.
22. Huang YW, Hu WW, Chen Z, Zhang LS, Shen HQ, Timmerman H, et al. Effect of the histamine H3-antagonist clobenpropit on spatial memory deficits induced by MK-801 as evaluated by radial maze in Sprague-Dawley rats. Behav Brain Res 2004;151: 287-93.
23. 25-35 peptide are attenuated by salvianolic acid B. Neuropharmacology 2011;61:1432-40.
24. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 1991;88:7247-51.
25. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25: 455-67.
26. 3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007;320:365-75.
27. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000;23:223-39.
28. 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Res 1996;731: 249-53.
29. 3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem Pharmacol 2007;73:1182-94.
30. Miyazaki S, Imaizumi M, Onodera K. Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice. Methods Find Exp Clin Pharmacol 1995a;17:653-8.
31. 3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plusmaze test in mice. Life Sci 1995b;57:2137-44.
32. Molinengo L, Di CG, Ghi P. Combined action of thioperamide plus scopolamine, diphenhydramine, or methysergide on memory in mice. Pharmacol Biochem Behav 1999;63:221-7.
33. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010;128:419-32.
34. Olariu A, Tran MH, Yamada K, Mizuno M, Hefco V, Nabeshima T. Memory deficits and increased emotionality induced by β-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 2001;108:1065-79.
35. Passani MB, Bacciottini L, Mannaioni PF, Blandina P. Central histaminergic system and cognition. Neurosci Biobehav Rev 2000;24:107-13.
36. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618-25.
37. 3 receptor and its gene transcripts in rat brain. Neuroscience 2002;114:173-93.
38. 3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 2010;10:153-69.
39. Selkoe DJ. Amyloid beta-protein precursor: newclues to the genesis of Alzheimer's disease. Curr Opin Neurobiol 1994;4:708-16.
40. 3 antagonists as wake-promoting and procognitive agents. Curr Top Med Chem 2008;8:988-1002.
41. 1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 2005;181:134-44.
42. 3 receptors. Mol Pharmacol 2002;62:389-97.
43. 3 ligands. Methods Find Exp Clin Pharmacol 1992;14:747-51.
44. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol Bull 1990;108:442-61.
45. Weiner I. The "2-headed" latent inhibitionmodel of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 2003;169: 257-97.
46. Weiner I, Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 2009;204:369-86.
47. Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of antidementia drugs. Pharmacol Ther 2000;88:93-113.
48. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250:279-82.
49. Zussy C, Brureau A, Delair B, Marchal S, Keller E, Ixart G, et al. Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid beta fragment in rats. Am J Pathol 2011;179:315-34.